MedTrace Logo

A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors

NCT06258408 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-11-17

No results posted yet for this study

Summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation phase and expansion phase.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

BB102 tablet

BB102 tablets will be administered orally once daily(QD).

Sponsors & Collaborators

  • Broadenbio Ltd., Co.

    lead INDUSTRY

Principal Investigators

  • Suxia Luo, MD · Henan Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-29
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06258408 on ClinicalTrials.gov